Search results for " morphine"

showing 10 items of 24 documents

Fentanyl Pectin Nasal Spray Versus Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A …

2016

Context Fentanyl products have shown superiority over oral opioids for the management of breakthrough cancer pain (BTcP). However, these studies did not use an appropriate patient selection, and drugs have been compared using a different rationale. Objectives The aim of this randomized, crossover, controlled study was to compare the efficacy and safety of fentanyl pectin nasal spray (FPNS) and oral morphine (OM), given in doses proportional to opioid daily doses. Methods Cancer patients with pain receiving ≥60 mg of OM equivalents/day and presenting with ≤3 episodes of BTcP/day were included. Patients received, in a randomized, crossover manner, FPNS or OM at doses proportional to the d…

Malefentanyl pectin nasal spraymedicine.medical_treatmentAdministration OralContext (language use)Fentanyl03 medical and health sciences0302 clinical medicinemedicineHumansCancer painGeneral NursingNursing (all)2901 Nursing (miscellaneous)Pain MeasurementAnalgesicsCross-Over StudiesMorphinebusiness.industryNasal SpraysMiddle Agedbreakthrough painCrossover studyFentanylRegimenTreatment OutcomeAnesthesiology and Pain MedicineOpioidNasal sprayoral morphine030220 oncology & carcinogenesisAnesthesiaMorphinePectinsFemaleNeurology (clinical)businessCancer painbreakthrough pain; Cancer pain; fentanyl pectin nasal spray; oral morphine; Nursing (all)2901 Nursing (miscellaneous); Neurology (clinical); Anesthesiology and Pain Medicine030217 neurology & neurosurgerymedicine.drug
researchProduct

Slow release oral morphine versus methadone for the treatment of opioid use disorder

2019

ObjectiveTo assess the efficacy of slow release oral morphine (SROM) as a treatment for opioid use disorder (OUD).DesignSystematic review and meta-analysis of randomised controlled trials (RCTs).Data sourcesThree electronic databases were searched through 1 May 2018: the Cochrane Central Register of Controlled Trials, MEDLINE and EMBASE. We also searched the following electronic registers for ongoing trials: ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, Current Controlled Trials and the EU Clinical Trials Register.Eligibility criteria for selecting studiesWe included RCTs of all durations, assessing the effect of SROM on measures of treatment retention, heroin use…

Narcoticsmedicine.medical_specialtyAddictionAdministration OralCraving1681substance use treatmentHeroin03 medical and health sciences0302 clinical medicineSlow release oral morphine (SROM)Internal medicineOpiate Substitution TreatmentHumansMedicine1506030212 general & internal medicine10. No inequalityAdverse effectRandomized Controlled Trials as TopicMorphinebusiness.industryResearchsubstance misuseopioid use disorderOpioid use disorderGeneral MedicineOpioid-Related Disordersmedicine.disease3. Good healthmeta-analysisClinical trialoral morphineOpioid use disorderReducing heroin useDelayed-Action PreparationsMeta-analysisRelative riskmedicine.symptombusinessMethadone030217 neurology & neurosurgerymedicine.drugMethadoneBMJ Open
researchProduct

Low morphine doses in opioid-naive cancer patients with pain

2006

Cancer pain can be managed in most patients through the use of the analgesic ladder proposed by the World Health Organization. Recent studies have proposed to skip the second "rung" of the ladder by using a so-called "strong" opioid for moderate pain. However, usual doses of strong opioids commonly prescribed for the third rung of the analgesic ladder may pose several problems in terms of tolerability in opioid-naive patients. The aim of this multicenter study was to evaluate the efficacy and tolerability of very low doses of morphine in advanced cancer patients no longer responsive to nonopioid analgesics. A sample of 110 consecutive opioid-naive patients with moderate-to-severe pain were …

AdultMalePainWHO method cancer pain opioids morphineOpioidDose-Response RelationshipQuality of lifeNeoplasmsWHO methodMedicineHumansCancer painOpioid peptideGeneral NursingNursing (all)2901 Nursing (miscellaneous)AgedAnalgesicsDose-Response Relationship DrugCancer pain; Morphine; Opioids; WHO method; Adult; Aged; Analgesics Opioid; Dose-Response Relationship Drug; Female; Humans; Male; Middle Aged; Morphine; Neoplasms; Pain; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology (clinical); Neurology; Nursing (all)2901 Nursing (miscellaneous)Morphinebusiness.industryCancerMiddle Agedmedicine.diseaseAnalgesics OpioidClinical trialOpioidsTreatment OutcomeAnesthesiology and Pain MedicineTolerabilityOpioidNeurologyAnesthesiaMorphineFemaleNeurology (clinical)DrugbusinessCancer painmedicine.drug
researchProduct

Equipotent doses to switch from high doses of opioids to transdermal buprenorphine.

2008

INTRODUCTION: The aim of this study was to evaluate the equianalgesic ratio of transdermal buprenorphine (TD BUP) with oral morphine and TD fentanyl in a sample of consecutive cancer patients receiving stable doses of 120-240 mg of oral morphine or 50-100 microg of TD fentanyl, reporting adequate pain and symptom control. MATERIALS, METHODS, AND RESULTS: Patients receiving daily stable doses of opioids for more than 6 days, with no more than two doses of oral morphine (20 and 40 mg, respectively) as needed, were switched to TD BUP using a fentanyl-BUP ratio of 0.6:0.8 and an oral morphine-BUP ratio of 70:1. Opioid doses, pain and symptom intensity, global satisfaction, and number of breakth…

Maletransdermal buprenorphinePainAdministration CutaneousFentanylNeoplasmsHigh dosesMedicineHumansSymptom controlProspective StudiesOral morphineAgedDose-Response Relationship Drugbusiness.industryMiddle AgedEquianalgesicBuprenorphineAnalgesics OpioidFentanylOncologyPatient SatisfactionAnesthesiaFemaleTransdermal Buprenorphinehigh doses of opioidsbusinessCancer painmedicine.drugSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
researchProduct

Meaningful cut-off pain intensity for breakthrough pain changes in advanced cancer patients

2013

Abstract OBJECTIVES: To assess the level of pain intensity at which patients feel the impetus to ask for a breakthrough cancer pain (BTcP) medication, and level of pain intensity at which patients consider they have achieved acceptable pain control after receiving a BTcP medication. METHODS: A consecutive sample of patients who were receiving oral morphine equivalents equal to or more than 60 mg daily, and were prescribed rapid onset opioids for the management of episodes of BTcP, were included in the study. Focused educational activities regarding BTcP and numerical scales were established during hospital admission. At discharge patients were interviewed to find out what was the pain inten…

Malemedicine.medical_specialtyCoping (psychology)Palliative careBreakthrough PainPainSettore MED/42 - Igiene Generale E ApplicataCONSECUTIVE SAMPLEadvanced cancer patientNeoplasmsHumansPain ManagementMedicineOral morphineAgedPain MeasurementMorphinebusiness.industrybreakthrough pain; advanced cancer patients; epidemiologic studyGeneral MedicineMiddle Agedbreakthrough painAdvanced cancerAnalgesics OpioidClinical trialepidemiologic studyPhysical therapyFemalebusinessCancer pain
researchProduct

Fentanyl Buccal Tablet vs. Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Randomiz…

2015

Fentanyl products have shown superiority to oral opioids for the management of breakthrough cancer pain (BTcP). However, these studies did not use appropriate patient selection, and drugs have been compared by using different rationales.The aim of this randomized, crossover, controlled study was to compare efficacy and safety of fentanyl buccal tablets (FBTs) and oral morphine (OM), given in doses proportional to opioid daily doses.Cancer patients with pain receiving ≥60 mg or more of oral morphine equivalents per day and presenting with ≤3 episodes of BTcP per day were included. In a randomized, crossover manner, patients received FBT or OM at doses proportional to the daily opioid regimen…

Malefentanyl buccal tabletContext (language use)FentanylNeoplasmsmedicineHumansCancer painGeneral NursingNursing (all)2901 Nursing (miscellaneous)Pain MeasurementCross-Over StudiesMorphinebusiness.industrybreakthrough pain; Cancer pain; fentanyl buccal tablet; oral morphine; Anesthesiology and Pain Medicine; Neurology (clinical); Nursing (all)2901 Nursing (miscellaneous)Administration BuccalPatient PreferenceBuccal administrationMiddle Agedbreakthrough painCrossover studyAnalgesics OpioidFentanylRegimenTreatment OutcomeAnesthesiology and Pain MedicineOpioidoral morphineAnesthesiaMorphineFemaleNeurology (clinical)Cancer painbusinessmedicine.drug
researchProduct

Tapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer pain.

2014

Abstract Abstract Objective: The aim of this study was to assess the efficacy and tolerability of tapentadol (TP) for a period of 4 weeks in patients who were already treated by opioids. Methods: A convenience sample of 30 patients was selected for a prospective observational cohort study. Cancer patients who were receiving at least 60 mg of oral morphine equivalents were selected. Patients discontinued their previous opioid analgesics before starting TP, in doses calculated according the previous opioid consumption (1:3.3 ratio with oral morphine equivalents). The subsequent doses were changed according to the patients' needs for a period of 4 weeks. Oral morphine was offered as a breakthr…

MalePalliative careReceptors Opioid muAdverse effectSettore MED/42 - Igiene Generale E ApplicataCohort StudiesNeoplasmsReceptorsDrug Dosage CalculationsProspective StudiesAdverse effects; Cancer pain; Palliative care; TapentadolCancer painPain MeasurementAnalgesicsMorphineMedicine (all)General MedicineMiddle AgedTapentadolAnalgesics OpioidTapentadolTreatment OutcomeItalyTolerabilityAnesthesiaPalliative careFemaleDrugDrug Monitoringmedicine.drugCohort studyAdverse effects; Cancer pain; Palliative care; Tapentadol; Aged; Analgesics Opioid; Cohort Studies; Dose-Response Relationship Drug; Drug Dosage Calculations; Drug Monitoring; Female; Humans; Italy; Karnofsky Performance Status; Male; Middle Aged; Morphine; Neoplasms; Pain Management; Pain Measurement; Phenols; Prospective Studies; Receptors Opioid mu; Treatment Outcome; Pain; Medicine (all)PainOpioidDose-Response RelationshipPhenolsmedicineHumansPain ManagementKarnofsky Performance StatusAdverse effectAgedDose-Response Relationship DrugAdverse effectsbusiness.industryCancermedicine.diseaseOpioidmubusinessCancer pain
researchProduct

Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: A 4-week, nonrandomized, open-label, uncontrolled observational stu…

2009

OBJECTIVE: The aim of this study was to evaluate the effect and tolerability of low doses of transdermal (TD) buprenorphine patches in opioid-naive patients with cancer pain. METHODS: This was a nonrandomized, open-label, uncontrolled study in consecutive opioid-naive patients with advanced cancer and moderate pain. TD buprenorphine was initiated at a dose of 17.5 microg/h (0.4 mg/d), with patch changes every 3 days. Doses were then adjusted according to the clinical response. Pain intensity, opioid-related adverse effects, TD buprenorphine doses, and quality of life were monitored over 4 weeks. The time to dose stabilization and indexes of dose escalation were also calculated. RESULTS: Thi…

Malecancer painPainOpioidUncontrolled Studytransdermal buprenorphine cancer pain uncontrolled observational studyDose-Response RelationshipNeoplasmsmedicineHumansPharmacology (medical)Adverse effectAgedPain MeasurementIntractablePharmacologyAnalgesicsbusiness.industryopioidsCancermorphineMiddle Agedbuprenorphine; cancer pain; morphine; opioids; Administration Cutaneous; Aged; Analgesics Opioid; Buprenorphine; Dose-Response Relationship Drug; Female; Humans; Male; Middle Aged; Neoplasms; Pain Measurement; Pain Intractable; Quality of Life; Pharmacology; Pharmacology (medical)buprenorphinemedicine.diseaseClinical trialCutaneousTolerabilityAnesthesiaAdministrationQuality of LifeMorphineFemaleDrugCancer painbusinessmedicine.drugBuprenorphineClinical Therapeutics
researchProduct

Real-time Patterns of Behavior Following Nociceptive Stimulation in Rats

2016

The hot-plate test is employed, in rodents, to assess the analgesic properties of drugs. The surface where the animal is placed is normally maintained at a constant temperature around 50°C or 55°C. For this reason rat’s behavior, once placed on the heated surface, can be observed only for few seconds, and a necessary interruption occurs following an a priori-established cut-off to avoid tissue injuries. Such a narrow time window dampened the assessment of fine behavioral characteristics such as the temporal structure of behavior. In the present paper we demonstrate the possibility to apply a refined multivariate approach, known as T-pattern analysis (TPA), to describe the temporal character…

anxiety pain morphine hot-plate t-pattern analysis multivariate analysis rat.Settore BIO/09 - Fisiologia
researchProduct

Development and validation of a reliable method for studying the distribution pattern for opiates metabolites in brain

2012

Abstract Brain distribution pattern of “street” heroin metabolites (morphine and codeine) was investigated in two fatalities due to “acute narcotism”. A suitable sample pretreatment prior to solid-phase-extraction was developed to achieve a good recovery of the analytes and to eliminate the interfering species. After derivatization with MSTFA, samples were analyzed by GC/MS. Specificity, accuracy, precision and linearity of the method were evaluated; LOD and LOQ were, respectively, 10 ng/25 ng for morphine and 5 ng/10 ng for codeine. This method was applied to the analysis of six brain areas (hippocampus, frontal lobe, occipital lobe, nuclei, bulb and pons) coming from two cases of heroin-r…

AdultMaleClinical BiochemistryAnalytical chemistryPharmaceutical ScienceHippocampusGas Chromatography-Mass SpectrometryAnalytical ChemistryHeroinchemistry.chemical_compoundSettore MED/43 - Medicina LegaleLimit of DetectionDrug DiscoverymedicineHumansTissue DistributionDerivatizationSpectroscopyHeroin; Morphine; Codeine; Post-mortem brain specimenChromatographyMolecular StructureMorphineCodeineHeroin DependenceIllicit DrugsCodeineBrainReproducibility of ResultsPonsHeroinSubstance Abuse DetectionchemistryFrontal lobeMorphinePost-mortem brain specimenDrug OverdoseOccipital lobemedicine.drug
researchProduct